
CLAIMS

1. An anhydrous crystalline form, referred to as form H, of Cabazitaxel of formula (I)



(I)

wherein the anhydrous crystalline form has one or more of the following:

- an X-RPD pattern obtained using the copper wavelengths λ_1 and λ_2 of 1.54056 Å and 1.54439 Å, respectively, comprising distinctive reflections, expressed as 2-theta degrees values, at 5.8, 6.5, 8.1, 9.5, 10.9, 11.5, 12.2, 13.0, 14.1, 14.8, 16.8, 17.2, 19.0, 19.4, 20.1, 21.9 and 24.0 ± 0.2;
- an X-RPD pattern obtained using the copper wavelengths λ_1 and λ_2 of 1.54056 Å and 1.54439 Å, respectively, essentially as depicted in Figure 1;
- TG and DTA profiles obtained with a linear heating rate of 10°C/min essentially as depicted in Figure 3;
- a DSC profile obtained with a linear heating rate of 10°C/min essentially as depicted in Figure 4;

2. Pharmaceutical compositions containing the anhydrous crystalline form H according to claim 1 in admixture with at least one excipient suitable for the pharmaceutical use.